Department of Burn Orthopedics, Xingtai People's Hospital, China.
Adv Clin Exp Med. 2021 Apr;30(4):431-439. doi: 10.17219/acem/130594.
Keloid is a unique refractory syndrome characterized by a proliferation disorder of the fibroblasts. Recently, photodynamic therapy (PDT) has become a promising technique to modulate fibroblasts. However, use of the photosensitizer Phenalen-1-one (Ph1) in PDT for keloid remains to be explored.
This study investigated the efficacy of Ph1-PDT in the in vitro and in vivo models of keloid.
Cell viability was assessed with a Cell Counting Kit-8 (CCK-8) analysis in keloid fibroblasts. The migrated and invaded keloid fibroblasts after Ph1-PDT were detected using scratch and matrigel invasion assays in vitro. Flow cytometry measured the apoptosis changes. The protein concentrations and the mRNA expression of inflammatory modulators (interleukin 8 (IL-8) and IL-1β) were determined using enzyme-linked immunosorbent assay (ELISA) and real-time quantitative polymerase chain reaction (RT-qPCR) methods, respectively. Nude mice were used to perform the transplantation of keloid grafts. Western blot analysis measured the protein expression of CD31, CD34, tumor growth factor β1 (TGF-β1), and collagen 1 in keloid fibroblasts and grafts.
Our results revealed that Ph1-PDT significantly suppressed cell viability, migration and invasion, and enhanced the rate of cell apoptosis and caspase-3 expression in keloid fibroblasts. Moreover, in the nude mice model, Ph1-PDT decreased the volume of the graft and attenuated the vessel density by inhibiting the expression of vessel density biomarkers (CD31 and CD34) in keloid grafts. Furthermore, Ph1-PDT significantly inactivated the inflammatory mediators in keloid grafts. In addition, Ph1-PDT considerably attenuated the development of keloids by inhibiting TGF-β1 and collagen 1 proteins in keloid fibroblasts and grafts.
Ph1-PDT may suppress keloid progression by reducing vessel formation and inflammation, and promoting fibroblast apoptosis, suggesting a potential therapy method for keloid.
瘢痕疙瘩是一种独特的难治性综合征,其特征是成纤维细胞增殖失调。最近,光动力疗法(PDT)已成为调节成纤维细胞的一种有前途的技术。然而,光敏剂 Phenalen-1-one(Ph1)在 PDT 治疗瘢痕疙瘩中的应用仍有待探索。
本研究探讨了 Ph1-PDT 在瘢痕疙瘩的体外和体内模型中的疗效。
通过细胞计数试剂盒-8(CCK-8)分析评估瘢痕疙瘩成纤维细胞的活力。体外划痕和基质胶侵袭实验检测 Ph1-PDT 后迁移和侵袭的瘢痕疙瘩成纤维细胞。流式细胞术检测细胞凋亡变化。酶联免疫吸附试验(ELISA)和实时定量聚合酶链反应(RT-qPCR)方法分别测定炎症调节剂(白细胞介素 8(IL-8)和 IL-1β)的蛋白浓度和 mRNA 表达。使用裸鼠进行瘢痕疙瘩移植物移植。Western blot 分析检测瘢痕疙瘩成纤维细胞和移植物中 CD31、CD34、转化生长因子β1(TGF-β1)和胶原 1 的蛋白表达。
我们的结果表明,Ph1-PDT 显著抑制了瘢痕疙瘩成纤维细胞的活力、迁移和侵袭,并增强了细胞凋亡率和 caspase-3 的表达。此外,在裸鼠模型中,Ph1-PDT 通过抑制血管密度标志物(CD31 和 CD34)在瘢痕疙瘩移植物中的表达,降低了移植物的体积并减轻了血管密度。此外,Ph1-PDT 通过抑制瘢痕疙瘩成纤维细胞和移植物中 TGF-β1 和胶原 1 蛋白的表达,显著抑制了炎症介质的表达。
Ph1-PDT 通过减少血管形成和炎症反应,促进成纤维细胞凋亡,可能抑制瘢痕疙瘩的进展,为瘢痕疙瘩的治疗提供了一种潜在的方法。